FindTrial
Sign In

A clinical trial to compare the effects of topical tacrolimus 0.1% and topical tofacitinib 2% in patients with non-segmental vitiligo

Evaluation of comparative efficacy of topical tacrolimus 0.1% vs topical tofacitinib 2% in non segmental vitiligo 2% in non-segmental vitiligo - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/092473
Enrollment
44
Registered
2025-08-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Topical tofacitinib 2% ointment: Topical tofacitinib 2% ointment twice daily for 16 weeks Control Intervention1: Topical tacrolimus 0.1% ointment: Topical tacrolimus 0.1% ointment twice

Sponsors

Dr Itee Gaur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age more than 5 years 2) Clinical diagnosis of non-segmental vitiligo 3)Body surface area involvement less than or equal to 10% 4) Stable vitiligo (no new lesions in last 12 weeks) 5) Willingness for a 2 week washout if on prior topical therapy

Exclusion criteria

Exclusion criteria: 1) Segmental vitiligo 2) Pregnant or lactating women 3) Allergy to study medications 4) Recent (within 4 weeks) systemic immunosuppressants or phototherapy

Design outcomes

Primary

MeasureTime frame
Amount of repigmentation of lesions as assessed by Vitiligo Disease Improvement Score (VDIS)Timepoint: Baseline, Weeks 4, 8, 12, 16—

Secondary

MeasureTime frame
Adverse effectsTimepoint: Baseline, Weeks 4, 8, 12, 16;Objective assessment using physician global assessment scaleTimepoint: Baseline, Weeks 4, 8, 12, 16;Time to visible repigmentationTimepoint: Baseline, Weeks 4, 8, 12, 16;Patient satisfaction (VNS Score)Timepoint: Baseline, Weeks 4, 8, 12, 16—

Countries

India

Contacts

Public ContactDr Jasleen Kaur

Government Medical College and Hospital, Chandigarh

jasleenksandhu21@gmail.com9646481249

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026